Project Grant R01CA303975
Award Date 8/15/25
Completion Date 7/31/29
Dollars Obligated $2.5M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Oregon, USA
Similar Awards
- This $1,241,184 Project Grant was awarded on June 13, 2025 by the National Institute of Dental and Craniofacial Research (NIDCR), under the Oral Diseases and Disorders Research federal grant program (CFDA 93.121), to Oregon Health & Science University (OHSU) to develop short-wave infrared (SWIR) fluorophores for enhanced visualization of buried nerves during head and neck cancer surgery. The project aims to address the challenge of iatrogenic nerve injury, which is a major cause of morbidity...
- The Project Grant award of $657,168 from the National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) to The Trustees of the University of Pennsylvania will fund a study to complete IND-enabling preclinical studies and conduct a first-in-human clinical trial for a novel near-infrared fluorescent dye, JAS239, to guide lung cancer resection surgeries. The fluorescent dye is designed to target choline kinase A, an enzyme overexpressed in up to 85% of non-small cell lung...
- The University of California, Davis was awarded a $297,074 Project Grant on August 8, 2025 by the National Cancer Institute under the Cancer Detection and Diagnosis Research federal grant program (CFDA 93.394). The grant aims to integrate label-free fluorescence lifetime imaging (FLIM) technology into standard colonoscopy procedures to enhance the detection and characterization of colorectal lesions in real-time. The research project has three specific objectives: 1) Build a comprehensive...
- The National Cancer Institute (CFDA 93.394 - Cancer Detection and Diagnosis Research) awarded a $670,534 Project Grant to Northwestern University to develop an optical hyperspectral nanoscale chromatin analysis technology for colorectal cancer risk stratification. The goal is to create a screening test to identify patients who harbor advanced adenomas and should undergo colonoscopy, with a target of 99.5% negative predictive value, 95% sensitivity, and 80% specificity for advanced adenomas....
- This federal Project Grant award, funded by the National Cancer Institute under the Cancer Treatment Research program (CFDA 93.395), provides $400,000.00 to Onconaut Therapeutics Inc. to develop novel combination therapies for the treatment of colorectal cancer. The project aims to evaluate the efficacy of combining FOLFIRI chemotherapy with CHD1L inhibitors (OTI-600 series), which have demonstrated antitumor activity as single agents and potential synergistic effects when combined with...
- This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) will support the development of a "Spatial Profiling-Based Immune Hub Perturbation Platform" to improve immunotherapy for colorectal cancer. The $710,361 award to J. David Gladstone Institutes will fund research to create a novel experimental framework to systematically test and prioritize candidate genes and therapies based on their ability to induce effective anti-tumor immune hubs -...
- The National Cancer Institute awarded a $226,608 Project Grant under the Cancer Research Manpower program (CFDA 93.398) to The Leland Stanford Junior University (Stanford University) on December 17, 2024. The grant supports a project titled "INTEGRATING HIGHLY MULTIPLEXED IMMUNOFLUORESCENCE WITH LABEL-FREE 2D HYPERSPECTRAL CHEMICAL IMAGING TO INTERROGATE THE COLORECTAL CANCER TUMOR-INVASIVE FRONT". The project aims to develop a computational workflow that integrates advanced imaging...
- This $576,493.00 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) aims to develop sophisticated, self-calibrating near-infrared fluorescent probes that can quantitatively assess microviscosity variations and monitor protein misfolding/aggregation within live cells. The probes are designed to have enhanced water solubility, stability, and cell permeability to maximize biocompatibility and selectivity for detecting viscosity changes and protein...
- This $375,134 Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) supports research to develop a novel approach for reducing the off-target accumulation of chemotherapeutic nanomedicines. The key objectives are to characterize an innate immune response that can be leveraged to limit nanoparticle deposition in healthy tissues, thereby enhancing delivery to tumors and improving the efficacy of chemotherapy. The 5-year project, starting on March 1, 2025,...
- This $2,265,578 federal Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to Oregon Health & Science University supports research to understand the impact of androgen receptor (AR) signaling on anti-tumor function of conventional dendritic cells (cDCs) and its contribution to sex differences in cancer outcomes. The project aims to investigate how AR expression in cDCs affects their ability to prime anti-tumor T cell responses, with a focus on...